RARE

#1581
Ultragenyx Pharmaceutical Inc. - Common Stock
23.9 4 USD
+2.92%
Setor: Cuidados de saúde
Base: USD
Moeda do lucro: USD
Faixa diária
23.94
23.94
Faixa anual
18.29
42.37
Mudança diária
+2.92%
Mudança mensal
-2.17%
Mudança em 6 meses
-29.98%
Mudança anual
-31.34%
Fechamento anterior
23.2 6
Open
23.9 4
Mínimo
23.9 4
High
23.9 4
Volume
142
Abrir gráfico completo Full chart

Financials

Visão geral Relatórios Estatísticas
Trimestral Ano
  • Market Capitalization 2.36 B
  • Employee 1 371
  • Founded 2010
  • CEO Emil Kakkis
  • Website www.ultragenyx.com
  • Headquarter Delaware, United States
  • FIGI BBG001RWPDW6
  • Industry Biotecnologia
Receita total
Lucro líquido
Lucro básico por ação
Dívida total
Fluxo de caixa livre
Caixa e equivalentes de caixa
Índice preço/lucro
-3.95
Índice preço/fluxo de caixa
3.37

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases. Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami. Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA.

Notícias